ABUS240621C2000
- 1.00
- 0.000.00%
Arbutus Biopharma Newsroom
Express News | Morgan Stanley Reports 10.3% Passive Stake in Arbutus Biopharma Corp as of May 31- SEC Filing
Express News | HC Wainwright & Co. has reiterated its buy rating for arbutus biopharma (ABUS.US), with a target price adjusted from $5.00 to $5.00.
Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $4
Chardan Capital analyst Keay Nakae maintains $Arbutus Biopharma(ABUS.US)$ with a buy rating, and maintains the target price at $4.According to TipRanks data, the analyst has a success rate of 38.2% an
Arbutus Biopharma Down Over 8%, on Pace for Largest Percent Decrease Since April 2023 -- Data Talk
Arbutus Biopharma Corporation (ABUS) is currently at $3.33, down $0.30 or 8.26% --On pace for largest percent decrease since April 25, 2023, when it fell 12.46% --Currently down two of the past thre
Barinthus Biotherapeutics Presents Updated Data From Two Clinical Trials In Chronic Hepatitis B At EASL Congress 2024
In the HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants w
Express News | Treatment With Arbutus’ Imdusiran and Vtp-300 Achieves Statistical Significance in Lowering Hbsag Levels
HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $5 Price Target
HC Wainwright & Co. analyst Ed Arce reiterates Arbutus Biopharma with a Buy and maintains $5 price target.
H.C. Wainwright Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $5
H.C. Wainwright analyst Ed Arce maintains $Arbutus Biopharma(ABUS.US)$ with a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 40.0% and a
Treatment With Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:
Arbutus Biopharma Is Maintained at Buy by Chardan Capital
Arbutus Biopharma Is Maintained at Buy by Chardan Capital
Express News | Chardan Capital: Maintains buy rating for Arbutus Biopharma (ABUS.US) and adjusts target price from $4.00 to $4.00.
Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $4 Price Target
Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma with a Buy and maintains $4 price target.
JMP Securities Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $4
JMP Securities analyst Roy Buchanan maintains $Arbutus Biopharma(ABUS.US)$ with a buy rating, and maintains the target price at $4.According to TipRanks data, the analyst has a success rate of 32.2% a
Express News | Arbutus’ Imdusiran With Short Course Interferon Achieves Sustained Undetectable Hbsag, a Necessity for Hbv Functional Cure
RNAi Therapeutics and Technology Market Worth USD 5.36 Billion by 2031 at 16.6% CAGR- Exclusive Report by InsightAce Analytic Pvt. Ltd.
JERSEY CITY, N.J., June 4, 2024 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "RNAi Therapeutics and Technology Market by Type (Small interf
Arbutus to Participate in Jefferies Global Healthcare Conference
WARMINSTER, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a fu
Arbutus Biopharma Shareholders Approve Board Changes and Plan Expansion
Arbutus to Present Imdusiran Data at EASL Congress 2024
WARMINSTER, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to
Genevant Sciences And Arbutus Biopharma Win Dismissal Of An Action By Acuitas Therapeutics (Partnered With Pfizer On Vaccine Delivery Systems) Seeking A Declaratory Judgement That The Pfizer Comirnaty Vaccine Does Not Infringe Arbutus Patents
Genevant Sciences And Arbutus Biopharma Win Dismissal Of An Action By Acuitas Therapeutics (Partnered With Pfizer On Vaccine Delivery Systems) Seeking A Declaratory Judgement That The Pfizer Comirnaty
Sector Update: Health Care Stocks Softer Friday Afternoon
Health care stocks eased Friday afternoon with the NYSE Health Care Index down 0.1% and the Health Care Select Sector SPDR Fund (XLV) marginally higher. The iShares Biotechnology ETF (IBB) fell 0.3%.